Drostanolone Enanthate 200 mg — Magnus Pharmaceuticals

Description

Drostanolone Enanthate 200 mg Magnus Pharmaceuticals — drostanolone from Magnus Pharmaceuticals at 200 mg. DHT derivative; cannot aromatise and actively inhibits aromatase. Cosmetic hardening effect is most dramatic below 12% body fat — the classic pre-contest use-case.

Key Benefits

DHT-derivative — dry, hard, vascular look with no water retention
Anti-estrogenic side-activity — mild AI effect
Cutting and pre-contest staple, especially at low body-fat
Minimal sides at performance doses — clean compound
Stacks well with tren, test, and orals for cutting recomp
Each unit dosed at 200 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: propionate 300–500 mg/week split EOD or 3×/week; enanthate 400–600 mg/week split twice weekly. Cycles 8–10 weeks (prop) or 10–14 weeks (eno). Pre-contest protocols stretch to final 6 weeks before show.

How It Works

5α-reduced testosterone with a 2α-methyl group. DHT-derivative — does not aromatise. Mild anti-estrogenic activity via aromatase enzyme competition. High AR affinity. Androgenic but not aggressively so at typical doses.

Pharmacokinetics

Propionate ester: plasma half-life ~2 days. Enanthate: ~7 days. Prop needs EOD or M/W/F pinning; eno twice-weekly fine. Steady-state in 2 weeks (prop) or 4 weeks (eno).

Cycle & Stacking Guide

Cutting stack component, 8–14 weeks by ester. Classic pairing: test E 250 mg/week + masteron E 400 mg/week + (optional) tren or winstrol for final weeks. Works best at <15% body fat where the "dry" look actually shows.

Manufacturer Notes

Magnus Pharmaceuticals focuses on the research-chemical end of the market with detailed batch identifiers. Injectables use cotton-seed or grape-seed oil for reduced PIP.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Drostanolone Enanthate 200 mg Magnus Pharmaceuticals”

2D structural representation · PubChem CID 252748 ↗

Chemical Identity
#	CAS Registry Number	`13425-31-5`
Σ	IUPAC Name	[(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
F	Molecular Formula	C₂₇H₄₄O₃
M	Molecular Weight	416.64 g/mol
⌬	SMILES	`CCCCCCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CC[C@@H]4CC(=O)[C@@H](C)C[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`RVZQLOBJNFHWOK-JBDPFAERSA-N`
△	Melting Point	Oil (liquid at RT) °C
≋	Solubility	Insoluble in water; soluble in oils
t½	Biological Half-life	7-10 days (IM)
⊕	PubChem CID	252748 ↗

Pharmacological Profile
Anabolic Rating	62
Androgenic Rating	25
Aromatization	None
Hepatotoxicity	None
Detection Time	3 months

Known trade names: Masteron Enanthate, Mast E

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

2D structural representation · PubChem CID 224004 ↗

Chemical Identity
#	CAS Registry Number	`521-12-0`
Σ	IUPAC Name	[(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] propanoate
F	Molecular Formula	C₂₃H₃₆O₃
M	Molecular Weight	360.53 g/mol
⌬	SMILES	`CCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CC[C@@H]4CC(=O)[C@@H](C)C[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`VDIINQKPRNWKEH-GOGNSEEVSA-N`
△	Melting Point	124-126 °C
≋	Solubility	Insoluble in water; soluble in oils
t½	Biological Half-life	2.5 days (IM)
⊕	PubChem CID	224004 ↗

Pharmacological Profile
Anabolic Rating	62
Androgenic Rating	25
Aromatization	None
Hepatotoxicity	None
Detection Time	3 weeks

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

DHT-derived injectable — 2alpha-methyl modification at the A-ring confers resistance to 3alpha-HSD, allowing intact muscle-cell activity. Cannot aromatise. Weak AR binding in skeletal tissue but displaces estradiol from SHBG, increasing free-testosterone fraction of any concurrent testosterone — this is the mechanism behind the hardening clinical picture at low body-fat percentages. Effect is visibly null above 15% body fat; below 12%, the lean-tissue definition response becomes dose-responsive. Propionate ester mandates EOD injection schedule; PIP is common and dose-dependent — low-viscosity MCT or GSO carrier oil reduces it materially. Androgenic effects (scalp, prostate) occur but are limited to DHT-sensitive populations.

Known trade names: Masteron, Drostopro, Mastabol

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

Drostanolone Enanthate 200 mg Magnus Pharmaceuticals